- Study: Participation in diabetes education associated with greater ability to self-manage
- Obesity drug beloranib shows promise in Prader-Willi population in Phase 2 trials
- Study pinpoints protective genetic mutations for Type 2 diabetes
- Bydureon pen gets FDA approval
- Novo Nordisk launches new insulin device
SAN DIEGO — Amylin Pharmaceuticals and Takeda Pharmaceutical have halted development of a treatment for obesity in mid-stage clinical trials, the two companies said.
The companies said the decision to discontinue development of a therapy that combines pramlintide and metreleptin was based on "a commercial reassessment of the pramlintide/metreleptin program … [that] took into account a revised development plan, as well as evolving dynamics within he obesity therapeutic area."
Nevertheless, the companies said they would continue investigating other treatments for obesity.